Ian Strohbehn
8PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Sep 22, 2025
Response to Letter to the Editor, Re: The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study Open Forum Infect Dis. 2024 Dec 31;12(1):ofae756. doi: 10.1093/ofid/ofae756.Ian Strohbehn, Meghan Sise
|Jan 28, 2025
The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study.Ian A Strohbehn, Tianqi Ouyang, Meghan D Lee
|Feb 23, 2023
Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.Bruce C Tiu, Ian A Strohbehn, Sophia Zhao
|Aug 12, 2021
Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction.Ian A Strohbehn, Sarah Street, Donald Chute
|Dec 29, 2020
Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors.Harish Seethapathy, Nifasha Rusibamayila, Donald F Chute
|Dec 23, 2020
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.Harish Seethapathy, Meghan D Lee, Ian A Strohbehn
Pageof 2
